en · de · es · fr · pt
aod-9604-notes.peptides4800.com › News › Research And Regulatory Status — 2026 Update

Research And Regulatory Status — 2026 Update

By Editorial Desk · published 2025-08-10 · last reviewed 2025-09-08 · News

The short version of lipogenesis fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.

Research and Regulatory Status

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Related pages on this site

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Background from the literature

In 2009, in an article for The Atlantic entitled "The Revenge of Karl Marx", Hitchens frames the late-2000s recession in terms of Marx's economic analysis and notes how much Marx admired the capitalist system that he called for the end of, but says that Marx ultimately failed to grasp how revolutionary capitalist innovation was. Hitchens was an admirer of Che Guevara, yet in an essay written in 1997, he distanced himself from Che, and referred to the mythos surrounding him as a "cult". In 2004 he re-emphasized his positive view of Che, commenting that "[Che's] death meant a lot to me and countless like me at the time. He was a role model, albeit an impossible one for us bourgeois romantics insofar as he went and did what revolutionaries were meant to do – fought and died for his beliefs." He continued to regard Leon Trotsky and Vladimir Lenin as great men, and the October Revolution as a necessary event in the modernisation of Russia. In 2005, Hitchens praised Lenin's creation of "secular Russia" and his attacks on the Russian Orthodox Church, describing the church's power as "absolute warren of backwardness and evil and superstition". In God is not Great, Hitchens called Marxism his "own secular faith" that "has been shaken and discarded, not without pain." He referred to his period of Marxist faith as "when I was a Marxist." According to Andrew Sullivan, his last words were "Capitalism, downfall."

Na2B4O7 + 4 H2O2 + 2 NaOH → 2 Na2B2O4(OH)4 + H2O Sodium percarbonate, which is an adduct of sodium carbonate and hydrogen peroxide, is the active ingredient in such laundry products as OxiClean and Tide laundry detergent. When dissolved in water, it releases hydrogen peroxide and sodium carbonate. By themselves these bleaching agents are only effective at wash temperatures of 60 °C (140 °F) or above and so, often are used in conjunction with bleach activators, which facilitate cleaning at lower temperatures. Hydrogen peroxide has also been used as a flour bleaching agent and a tooth and bone whitening agent.

== Public awareness and solutions == Third-hand smoke is a relatively newly postulated and initially controversial concept, and public awareness of it is lower than that of passive smoke. A 2013 study with six focus groups in metro and rural Georgia (USA) asked participants whether they had heard of THS, most of the participants had not heard about it and did not know what third-hand smoke was. Research on THS is growing, but it does not compare to the 40 years of research on the effects of passive smoke. Yet, it is estimated that 5%-60% of passive smoke-related harm may be attributable to third-hand smoke exposure. THS poses such a risk because its exposure can linger much longer than passive smoke. Third-hand smoke-contaminated surfaces like carpet, walls, and car interiors are also especially hard to clean, whereas passive smoke can be removed with ventilation. Smoking rates in the United States have fallen considerably from 42.4% in 1965 to 17.8% in 2016. However, the downward trend is slowing, and it is estimated that 23% to 42% of adults in America with low education or living in poverty still smoke. This exposes millions of nonsmokers, many of whom are children. THS awareness campaigns are growing and primarily focus on the health risks for young children. A 2014 study published in Pediatrics demonstrated that parents are more likely to attempt to quit smoking if they become convinced that third-hand smoke is harmful to children and are more likely to have smoke-free home and car policies if they are aware of the dangers of third-hand smoke.

Sources: en.wikipedia.org

Reference notes

Directed by Michael Bate and co-written by Bate and David McDonald, the production was inspired by a March 1973 interview that Bate conducted with Parsons, which became Parsons' last recorded conversation. In 2012, Swedish folk duo First Aid Kit released the single "Emmylou" from the album The Lion's Roar. The song's chorus is a lyrical acknowledgment of the Gram Parsons and Emmylou Harris singing partnership. In the fall of 2012 Florida festival promoter and musician Randy Judy presented his bio-musical Farther Along – The Music and Life of Gram Parsons at Magnoliafest at the Spirit of the Suwannee Music Park. Tribute bands include Cleveland's New Soft Shoe and, out of St. Paul, The Gilded Palace Sinners. In 2022, Dave Prinz, co-founder of Amoeba Music, rediscovered Gram Parsons' "Last Roundup" tapes featuring Emmylou Harris with Gram Parsons and the Fallen Angels. Prinz initiated a campaign to fund the release independently, in partnership with Polly Parsons. The campaign launched on November 17, 2022, and was fully backed. Gram Parsons & The Fallen Angels' "The Last Roundup: Live from The Bijou Café in Philadelphia 3/16/73" was released on limited-edition vinyl on Friday, November 24, 2023, and was considered one of the hits of Record Store Day 2023. In 2021, Zak Bagans and his crew on the hit TV show Ghost Adventures, with a special guest, investigated the Joshua Tree Inn to bring both closure and peace to the Parsons family. In 2026, a restaurant named "Grievous Angel" (named after the Gram Parsons album title) opened in Lakeland, Florida.

== Further reading == Ferner S, Koszmagk R, Lehmann A, Heilmann W (1990). "[Reference values of Na(+) and Cl(-) concentrations in adult sweat]". Zeitschrift für Erkrankungen der Atmungsorgane (in German). 175 (2): 70–5. PMID 2264363. Nadel ER, Bullard RW, Stolwijk JA (July 1971). "Importance of skin temperature in the regulation of sweating". Journal of Applied Physiology. 31 (1): 80–7. Bibcode:1971JAPh...31...80N. doi:10.1152/jappl.1971.31.1.80. PMID 5556967. Sato K, Kang WH, Saga K, Sato KT (April 1989). "Biology of sweat glands and their disorders. I. Normal sweat gland function". Journal of the American Academy of Dermatology. 20 (4): 537–63. doi:10.1016/S0190-9622(89)70063-3. PMID 2654204.

==== Dendrotoxins ==== Dendrotoxins inhibit neurotransmissions by blocking the exchange of positive and negative ions across the neuronal membrane lead to no nerve impulse, thereby paralyzing the nerves. Snake example: mambas

Sources: en.wikipedia.org

Notes from published material

== Definition == Conventionally, merocyanine class includes streptocyanines and their analogues where both the nitrogen atom and carbonyl group (or any other electron-withdrawing group containing a multiple carbon-heteroatomic bond, e.g. amino group) can form part of a heterocyclic system. Like ionic cyanines, merocyanines contain two terminal heteroatoms and a polymethine chain in their chromophores.

== Medical uses == Amitriptyline/chlordiazepoxide is used for the treatment of moderate to severe depression associated with moderate to severe anxiety. It has shown to be more effective in treating symptoms of anxiety, irritability, and hostility in patients with comorbid depression and anxiety than amitriptyline alone. It also has a quicker onset time than either amitriptyline or chlordiazepoxide on their own.

=== Controversies === Alteplase is underused in low- and middle-income countries. This may be due to its high cost and the fact that it is often not covered by health insurance. There may be citation bias in the literature on alteplase in ischemic stroke, as studies reporting positive results for tissue plasminogen activator are more likely to be cited in following studies than those reporting negative or neutral results. There is a sex difference in the use of intravenous tissue plasminogen activator, as it is less likely to be used for women with acute ischemic stroke than men. However, this difference has been improving since 2008.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

Network